SOURCE: Endexx Corporation

January 28, 2015 07:00 ET

Endexx Announces Positive Results of Initial Diabetic Neuropathy Patient Study

Patients Demonstrate Potential Therapeutic Benefits From M3 CBD-Rich Hemp Oil

CAVE CREEK, AZ--(Marketwired - Jan 28, 2015) - Endexx Corporation (OTC PINK: EDXC) announced today that phase 1 of a diabetic neuropathy case study with the purpose of observing if M3CBD, a uniquely formulated CBD and CBD-A rich industrial hemp extract would mitigate or alleviate pain when inhaled through an electronic vaporizer, has been successfully completed. The case study was initiated in late November 2014 by Dr. Daniel Kiddy, as a voluntary patient study.

Endexx provided its M3Vape starter kit to the study and food grade hemp oil extract from imported industrial hemp grown on a certified non-GMO eco-farm under strict organic practices. The batch used in the study was 100% natural and, free of all contaminants, pesticides, mold, bacteria and heavy metals. The hemp oil contained a rich blend of phytocannabinoids, including CBD, CBD-A, CBG, and CBC, and Citronellol, a powerful terpenoid, that together interact with cannabinoid receptors in what is known as the "entourage effect."

Daniel Kiddy, DPM, compiled and documented preliminary results for phase 1 with the participation of thirteen volunteer patients, all of whom suffer from diabetic neuropathy. The participants administered a minimal dose of the oil through vaporizer inhalation three times a day. Results can be summarized as follows:

  • Of the thirteen volunteers who participated in the trial, five did not follow the dosage protocol and are excluded from the results.

  • Seven out of eight patients reported a decrease in pain level with improvements ranging from slight to as much as 75%, with one patient reporting being free of pain for the last 5 days of phase 1. One patient suffering from chronic migraine headaches reduced the use of prescribed pain medication (Sumatriptan) by 40%. Four patients stated improved sleep, feeling refreshed, energized or free of pain when waking up, while two patients experienced mood improvement, feeling happier and less depressed. One patient who experienced much improved sleep and reduced depression did not however experience any decrease in pain level. No patient reported adverse reactions.

The choice of electronic vaporizer as a patient friendly delivery system was prompted by CBD's enhanced bioavailability and efficacy through inhalation. Cannabidiol has been shown in numerous human trials to be five times more bioavailable when inhaled than when taken orally.

While these results are purely anecdotal and only provide very limited and incomplete information that is in no way meant to be conclusive, they nevertheless supply critical feedback for doctors and patients alike and are designed to increase public awareness of the potential therapeutic and wellness properties of high grade, naturally occurring hemp extracts that are rich in cannabidiol and other phytocannabinoids. The trial is ongoing and seeks to add to a body of existing data and to inspire more wide scale research and encourage advanced clinical trials on the specific role of certain cannabinoids, including CBD in particular, in exerting significant analgesic effects in various chronic pain conditions, without psychoactive or adverse effects.

Dr. Kiddy stated: "Patients demonstrated significant reduction in pain and fatigue. Patients also experienced better sleep and more energy associated with use of the M3CBD oil. During the first thirty days, patients were instructed to use the product three times a day. Advancing into the second phase patients are instructed to increase to five times per day. As a result of this initial study, our expectations were exceeded in a very short period of time. We believe that ongoing studies and observations are warranted in order to establish a better understanding of the potential of this natural remedy."

About Endexx
Endexx provides innovative medical marijuana management and technology solutions. The company has two technology products that launched in 2014 -- the M3hub and the Autospense. Both products provide essential solutions to promote regulatory compliance and full accountability through "seed to sale" inventory management and tracking. Based on principles developed by the pharmacological industry, the m3hub database is the first standardized software platform for tracking pharmaceutical grade marijuana to support a Centralized Medical Marijuana Industry Repository and maintain compliance with the laws of State government and local regulatory bodies, as well as, provide a smooth transition to the eventual Federal mandates. The AutospenseTM is a high-tech marijuana inventory control and dispensing machine, which provides up to the minute accounting details and protects the security of the product as well as the patient. By automating the dispensing process, Autospense™ increases productivity and reduces costs for marijuana retailers, while enhancing their service quality by reducing transaction time for customers. www.endexx.com, www.m3hub.com, www.autospense.com

Safe Harbor Notice
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors. The Company undertakes no obligation to update any forward-looking statements.

Contact Information

  • For further investor and media information, contact:
    Endexx Corporation
    Todd Davis
    Chairman & CEO
    endexx@endexx.com
    480-595-6900